{"id":589189,"date":"2022-03-02T15:22:01","date_gmt":"2022-03-02T15:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=589189"},"modified":"2022-03-02T15:22:01","modified_gmt":"2022-03-02T15:22:01","slug":"multiple-system-atrophy-pipeline-report-2022-insights-into-the-current-therapies-emerging-drugs-and-treatment-outlook-key-companies-biogen-corestem-theravance-biohaven-pharma-and-alterity","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/multiple-system-atrophy-pipeline-report-2022-insights-into-the-current-therapies-emerging-drugs-and-treatment-outlook-key-companies-biogen-corestem-theravance-biohaven-pharma-and-alterity_589189.html","title":{"rendered":"Multiple System Atrophy Pipeline Report, 2022 : Insights into the Current Therapies, Emerging Drugs, and Treatment Outlook | Key Companies &#8211; Biogen, Corestem, Theravance, Biohaven Pharma, and Alterity"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Multiple System Atrophy Pipeline Report, 2022 : Insights into the Current Therapies, Emerging Drugs, and Treatment Outlook | Key Companies - Biogen, Corestem, Theravance, Biohaven Pharma, and Alterity\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Multiple System Atrophy Pipeline Report, 2022 : Insights into the Current Therapies, Emerging Drugs, and Treatment Outlook | Key Companies - Biogen, Corestem, Theravance, Biohaven Pharma, and Alterity\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cMultiple System Atrophy Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Multiple System Atrophy Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Multiple System Atrophy Pipeline<\/strong> report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Multiple System Atrophy Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/cf2abdf0954969740e14171004afddfb.jpg\" alt=\"Multiple System Atrophy Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-system-atrophy-msa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Multiple System Atrophy Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Multiple System Atrophy<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Multiple System Atrophy Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Multiple System Atrophy<\/strong> <strong>key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Multiple System Atrophy Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Multiple System Atrophy market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/multiple-system-atrophy-msa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/multiple-system-atrophy-msa-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Multiple System Atrophy Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The dynamics of the <strong>Multiple System Atrophy market<\/strong> is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Multiple System Atrophy (MSA) Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Biogen<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Corestem<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Theravance Biopharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Biohaven Pharmaceutical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Alterity Therapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Multiple System Atrophy (MSA) Therapies Covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">TD-9855<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BHV-3241<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BIIB101<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Safinamide<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CS10BR05<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ATH434<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/multiple-system-atrophy-msa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/multiple-system-atrophy-msa-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Multiple System Atrophy&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Multiple System Atrophy Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Multiple System Atrophy &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Multiple System Atrophy Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Multiple System Atrophy Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Multiple System Atrophy Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Multiple System Atrophy Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Multiple System Atrophy Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Multiple System Atrophy Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Multiple System Atrophy Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Multiple System Atrophy Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Multiple System Atrophy Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Visit to get the sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/multiple-system-atrophy-msa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/multiple-system-atrophy-msa-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>More Trending&nbsp;Healthcare Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/malignant-pleural-mesothelioma-market\">Malignant Pleural Mesothelioma (MPM) Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Malignant Pleural Mesothelioma (MPM) Market is anticipated to grow in the coming years owing to the improvement in healthcare spending across the world, rising prevalence, and the active participation of the key companies in the therapeutics domain such as <strong>Sellas, Polaris Pharma, Targovax,<\/strong> among others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=multiple-system-atrophy-pipeline-report-2022-insights-into-the-current-therapies-emerging-drugs-and-treatment-outlook-key-companies-biogen-corestem-theravance-biohaven-pharma-and-alterity\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=multiple-system-atrophy-pipeline-report-2022-insights-into-the-current-therapies-emerging-drugs-and-treatment-outlook-key-companies-biogen-corestem-theravance-biohaven-pharma-and-alterity\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP \u201cMultiple System Atrophy Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Multiple System Atrophy Market. The Multiple System Atrophy Pipeline report embraces in-depth commercial and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/multiple-system-atrophy-pipeline-report-2022-insights-into-the-current-therapies-emerging-drugs-and-treatment-outlook-key-companies-biogen-corestem-theravance-biohaven-pharma-and-alterity_589189.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-589189","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/589189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=589189"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/589189\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=589189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=589189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=589189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}